key: cord-0708751-mgwx0u6x authors: Pulliam, Juliet R. C.; van Schalkwyk, Cari; Govender, Nevashan; von Gottberg, Anne; Cohen, Cheryl; Groome, Michelle J.; Dushoff, Jonathan; Mlisana, Koleka; Moultrie, Harry title: Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa date: 2022-03-15 journal: Science DOI: 10.1126/science.abn4947 sha: bfa1845b532f593242983e84394d43355353236c doc_id: 708751 cord_uid: mgwx0u6x Here, we provide two methods for monitoring reinfection trends in routine surveillance data to identify signatures of changes in reinfection risk and apply these approaches to data from South Africa’s SARS-CoV-2 epidemic to date. While we found no evidence of increased reinfection risk associated with circulation of Beta (B.1.351) or Delta (B.1.617.2) variants, we find clear, population-level evidence to suggest immune evasion by the Omicron (B.1.1.529) variant in previously infected individuals in South Africa. Reinfections occurring between 01 November 2021 and 31 January 2022 were detected in individuals infected in all three previous waves, and there has been an increase in the risk of having a third infection since mid-November 2021. 1 To assess validity of the data linkage procedure and thus verify whether individuals identified as having suspected reinfections did in fact have positive test results at least 90 days apart, we conducted a manual review of a random sample of suspected second infections occurring on or before 20 January 2021 (n=585 of 6026; 9.7%). This review compared fields not used for linkages (address, cell-phone numbers, email addresses, facility, and health-care providers) between records in the NMC-SS and positive test line lists. Where uncertainty remained and contact details were available, patients or next-of-kin were contacted telephonically to verify whether the individual had received multiple positive test results. Of the 585 randomly selected individuals with possible reinfections in the validation sample, 562 (96%) were verified as the same individual based on fields not used to create the linkages; the remaining 23 (4%) were either judged not a match or to have insufficient evidence (details captured by the clinician or testing laboratory) to determine whether the records belonged to the same individual. Between 5 and 11 December 2022, server issues at the National Health Laboratory Service's Central Data Warehouse prevented one of the identifiers used in the probabilistic linkages from being pulled through into the dataset. Retrospective evaluation of the use of the identifier revealed that it had been required for 0.3% of the links made prior to this time. The impact of this data discrepancy is therefore thought to be minimal. We compared the age, gender, and province of individuals with suspected reinfections to individuals eligible for reinfection (i.e., who had a positive test result at least 90 days prior to 31 January 2022). We did not calculate overall incidence rates by wave because the force of infection is highly variable in space and time, and the period incidence rate is also influenced by the temporal pattern of when people become eligible for reinfection. Incidence rate estimates would therefore be strongly dependent on the time frame of the analysis and not comparable to studies from other locations or time periods. The uncertainty intervals shown in Figure 5 were constructed to take into account both measurement error and uncertainty in the assumed observation probabilities. To capture uncertainty in the observation probabilities, we uniformly sampled 1,000 values from the polygon of plausible values for and 2 ( Figure S8 ). For each parameter combination, we used the model described in the main text (approach 2) to reconstruct the numbers of primary and second infections by day, as well as the relevant susceptible populations at risk. We then used each reconstructed data set to construct a 95% confidence interval for the associated Poisson rate, after Sahai and Kurshid (32) , and for the associated incidence rate ratio, after Ulm (33) . The confidence limits for the hazard coefficients were approximated by dividing the confidence limits for the Poisson rates by the reconstructed value of the total incidence for each reconstructed data set. The final uncertainty intervals were then constructed from the distribution of confidence limits based on the 1,000 reconstructed data sets. The median value presented in Figure 5 is the median estimate from across the data sets, and the confidence limits represent the 2.5% and 97.5% quantiles of the lower and upper confidence limits, respectively. Suspected reinfections were identified in all nine provinces ( Figure S1 ). The reinfection rate was highest in Western Cape, where 20,952 of 516,857 eligible primary infections (4.05%) had suspected reinfections and lowest in Northern Cape ( Relative to individuals with no identified reinfection, reinfections were concentrated in adults between the ages of 20 and 55 years ( Figure S2A ). The age distribution of second infections was consistent across waves ( Figure S2B ). Numbers for all age group-sex combinations are provided in Table S2. 3 Sensitivity analysis of hazard ratio estimates to assumed observation probabilities for primary and second infections. Estimates are shown for the full range of probabilities for which the overall mean relative hazard is between 0 and 1. The white polygon encloses the most plausible estimates (i.e. consistent with relative reinfection risk observed in the SIREN study (3) and observation probabilities for primary infection consistent with estimates based on seroprevalence data (4)). For all parameter combinations in the plausible range, 2 > , suggesting that having had a previous test is a good marker for who will test again. Top: Mean relative empirical hazard for reinfections versus primary infections in each wave, as a function of assumed observation probabilities for primary infections ( ) and reinfections ( 2 ). A: wave 1, B: wave 2, C: wave 3. Bottom: Percent change in the mean relative empirical hazard for reinfections versus primary infections in waves 2 (D) and 3 (E) relative to wave 1, as a function of assumed observation probabilities for primary infections ( ) and reinfections ( 2 ). Sensitivity analysis of empirical hazard ratio estimates to assumed observation probability for second infections among individuals whose first infection was undetected ( ). In the main analysis we assume that this observation probability is equivalent to other individuals who have not yet had a detected infection ( = , or a scaling factor of 1). Here, we compare this to the case when this probability is equal to 0 ( = 0, or a scaling factor of 0). We consider these to be bounding cases. The figure shown here is for = 0.1 and 2 = 0.5. Detection of a SARS-CoV-2 variant of concern in South Africa GISAID: Global initiative on sharing all influenza data -from vision to reality Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa The daily COVID-19 effective reproductive number (R) in South Africa: Week The daily COVID-19 effective reproductive number (R) in South Africa: Week Bounding the levels of transmissibility & immune evasion of the Omicron variant in South Africa Network for Genomic Surveillance in South Africa; COMMIT-KZN Team, Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum SARS-CoV-2 Omicron variant neutralization in serum from vaccinated and convalescent persons Considerable escape of SARS-CoV-2 Omicron to antibody neutralization SARS-CoV-2 reinfection trends in South Africa: Analysis of routine surveillance data Protection against the Omicron variant from previous SARS-CoV-2 infection Report 49: Growth, population distribution and immune escape of Omicron in England" (WHO Collaborating Centre for Infectious Disease Modelling, MRC Centre for Global Infectious Disease Analysis SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefing 34 Quantifying the risk of SARS-CoV-2 reinfection over time SARS-CoV-2 incidence, transmission and reinfection in a rural and an urban setting: Results of the PHIRST-C cohort study SIREN Study Group, SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: A large, multicentre, prospective cohort study (SIREN) SARS-CoV-2 variants of concern and variants under investigation in England Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 Prevalence of anti-SARS-CoV-2 antibodies among blood donors in South Africa during the period mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected With SARS-CoV-2 Neutralizing response against variants after SARS-CoV-2 infection and one dose of BNT162b2 Health Department adds antigen tests to country's official COVID-19 stats Inference from iterative simulation using multiple sequences Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa Statistics in Epidemiology: Methods, Techniques and Applications A simple method to calculate the confidence interval of a standardized mortality ratio (SMR)